a lot can happen 5 weeks before spp deadline, page-22

Imperatore your ignorance is excused

Yes both DNDN and PRR are involved in the area of cellular immunotherapy, DNDN for prostate and PRR for ovarian.

DNDN looks like it will have the 1st successful immunotherapy for cancer approved by the FDA. The road for DNDN has been long and challenging and in the process the clinical trials to get their product approved they have spent around US$100 million. DNDN's early clinical phase I and II data was quite impressive and hence why they attracted the required funding. PRR's data thus far is not as impressive and this is why the company needs to conduct many more trials that will chew up many tens of millions of $$$.

People like Ian Frazer are highly credible memebers of a SAB and can add a lot in the overall scheme of things but their involvement by no means provides a guarantee of commercial success. The ex Pfizer clinical trials woman is just a hired gun IMO.

Finally a SP of DNDN of $29.51 is irrelvant IMO, its the equity value that counts and how many more hundreds of millions of shares get issued in PRR before it is armed with data that is robust enough to attract funding in (a) the required levels and (b) at an appropriate valuation.

At the current rate there will be many billions of shares on issue by PRR before it even gets to where DNDN was 3-4 years ago. A $300m market cap at that time might be appropriate and assuming 2 billion shares on issue would equate to a SP of PRR of 15c.

Rgds

Prof.